[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fod5qXBITjmkziNo0foqNyunOhvqZoPceT2OUpIkK6mM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Gulhane School of Medicine",[4],67,false,8,0,21088,47,[13,16,19,21,23,26,28,31],{"name":14,"count":15},"Diabetes Mellitus",5,{"name":17,"count":18},"Proteinuria",4,{"name":20,"count":18},"Idiopathic Hypogonadotropic Hypogonadism",{"name":22,"count":18},"Hypogonadism",{"name":24,"count":25},"Chronic Kidney Disease",3,{"name":27,"count":25},"Catheter Blockage",{"name":29,"count":30},"Diabetic Nephropathy",2,{"name":32,"count":30},"Hypogonadotrophic Hypogonadism",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,86,120,153,187,219,238,264,282,300,326,344,367,390,415,433,451,469,492,515,540,558],{"intervention":43,"totalTrials":25,"cells":44},"ramipril",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":84},{"trials":46,"activeCount":9},[],{"trials":48,"activeCount":9},[],{"trials":50,"activeCount":9},[],{"trials":52,"activeCount":9},[],{"trials":54,"activeCount":9},[55,66,77],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":65},"NCT00893425","Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria","COMPLETED",[39],"2009-03","2009-04","2008-01",78,[17,29,24],[43],{"nctId":67,"briefTitle":68,"status":58,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":76},"NCT00674596","The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria",[39],"2008-03","2006-01",60,[74,17,75],"Diabetes","Renin Angiotensin System",[43],{"nctId":78,"briefTitle":79,"status":58,"phases":80,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":81,"interventions":82},"NCT01703234","FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients",[39],[17,29,24],[83],"Ramipril",{"trials":85,"activeCount":9},[],{"intervention":87,"totalTrials":30,"cells":88},"Testosterone 250mg",{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":95,"PHASE4":97,"NA":118},{"trials":90,"activeCount":9},[],{"trials":92,"activeCount":9},[],{"trials":94,"activeCount":9},[],{"trials":96,"activeCount":9},[],{"trials":98,"activeCount":9},[99,109],{"nctId":100,"briefTitle":101,"status":58,"phases":102,"primaryCompletion":103,"start":104,"enrollment":105,"conditions":106,"interventions":107},"NCT02171390","Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy",[39],"2012-06","2008-08",130,[32],[87,108],"Testosteron 50 mg transdermal gel",{"nctId":110,"briefTitle":111,"status":58,"phases":112,"primaryCompletion":113,"start":104,"enrollment":114,"conditions":115,"interventions":116},"NCT01533129","The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism",[39],"2011-04",106,[32],[117,87],"Testogel 50 mg transdermal gel",{"trials":119,"activeCount":9},[],{"intervention":121,"totalTrials":30,"cells":122},"Sevelamer",{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":151},{"trials":124,"activeCount":9},[],{"trials":126,"activeCount":9},[],{"trials":128,"activeCount":9},[],{"trials":130,"activeCount":9},[],{"trials":132,"activeCount":9},[133,144],{"nctId":134,"briefTitle":135,"status":58,"phases":136,"primaryCompletion":137,"completion":138,"start":62,"enrollment":139,"conditions":140,"interventions":142},"NCT01135615","Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)",[39],"2010-04","2010-05",100,[141],"We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.",[121,143],"calcium acetate",{"nctId":145,"briefTitle":146,"status":58,"phases":147,"conditions":148,"interventions":150},"NCT00486772","Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD",[39],[149],"Vascular Diseases",[121],{"trials":152,"activeCount":9},[],{"intervention":154,"totalTrials":30,"cells":155},"Amlodipine",{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":185},{"trials":157,"activeCount":9},[],{"trials":159,"activeCount":9},[],{"trials":161,"activeCount":9},[],{"trials":163,"activeCount":9},[],{"trials":165,"activeCount":9},[166,177],{"nctId":167,"briefTitle":168,"status":58,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT00921570","The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension",[39],"2009-05","2008-02",105,[74,174,17],"Hypertension",[154,176],"Valsartan",{"nctId":178,"briefTitle":179,"status":58,"phases":180,"primaryCompletion":170,"completion":170,"start":171,"enrollment":181,"conditions":182,"interventions":184},"NCT01738945","Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose",[39],32,[183],"We Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria.",[154],{"trials":186,"activeCount":9},[],{"intervention":188,"totalTrials":30,"cells":189},"Testosterone",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":217},{"trials":191,"activeCount":9},[],{"trials":193,"activeCount":9},[],{"trials":195,"activeCount":9},[],{"trials":197,"activeCount":9},[],{"trials":199,"activeCount":9},[200,209],{"nctId":201,"briefTitle":202,"status":58,"phases":203,"primaryCompletion":204,"completion":205,"start":170,"enrollment":206,"conditions":207,"interventions":208},"NCT02111473","The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism",[39],"2012-05","2014-04",49,[22],[188],{"nctId":210,"briefTitle":211,"status":58,"phases":212,"primaryCompletion":205,"completion":205,"start":213,"enrollment":214,"conditions":215,"interventions":216},"NCT02111434","Visceral Adiposity Index and Triglyceride\u002FHigh-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment",[39],"2013-07",150,[22],[188],{"trials":218,"activeCount":9},[],{"intervention":108,"totalTrials":220,"cells":221},1,{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":236},{"trials":223,"activeCount":9},[],{"trials":225,"activeCount":9},[],{"trials":227,"activeCount":9},[],{"trials":229,"activeCount":9},[],{"trials":231,"activeCount":9},[232],{"nctId":100,"briefTitle":101,"status":58,"phases":233,"primaryCompletion":103,"start":104,"enrollment":105,"conditions":234,"interventions":235},[39],[32],[87,108],{"trials":237,"activeCount":9},[],{"intervention":239,"totalTrials":220,"cells":240},"Human insulin",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":262},{"trials":242,"activeCount":9},[],{"trials":244,"activeCount":9},[],{"trials":246,"activeCount":9},[],{"trials":248,"activeCount":9},[],{"trials":250,"activeCount":9},[251],{"nctId":252,"briefTitle":253,"status":58,"phases":254,"primaryCompletion":61,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT01013402","Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia",[39],"2009-08","2008-12",51,[259],"Hypoglycemia",[239,261],"Human Insulin",{"trials":263,"activeCount":9},[],{"intervention":143,"totalTrials":220,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":280},{"trials":267,"activeCount":9},[],{"trials":269,"activeCount":9},[],{"trials":271,"activeCount":9},[],{"trials":273,"activeCount":9},[],{"trials":275,"activeCount":9},[276],{"nctId":134,"briefTitle":135,"status":58,"phases":277,"primaryCompletion":137,"completion":138,"start":62,"enrollment":139,"conditions":278,"interventions":279},[39],[141],[121,143],{"trials":281,"activeCount":9},[],{"intervention":176,"totalTrials":220,"cells":283},{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":298},{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[],{"trials":289,"activeCount":9},[],{"trials":291,"activeCount":9},[],{"trials":293,"activeCount":9},[294],{"nctId":167,"briefTitle":168,"status":58,"phases":295,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":296,"interventions":297},[39],[74,174,17],[154,176],{"trials":299,"activeCount":9},[],{"intervention":301,"totalTrials":220,"cells":302},"Testosteron 250mg",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":324},{"trials":304,"activeCount":9},[],{"trials":306,"activeCount":9},[],{"trials":308,"activeCount":9},[],{"trials":310,"activeCount":9},[],{"trials":312,"activeCount":9},[313],{"nctId":314,"briefTitle":315,"status":58,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":322},"NCT01454011","The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups",[39],"2011-02","2008-09",140,[321],"Secondary Hypogonadism",[301,323],"Testosterone 50mg transdermal application",{"trials":325,"activeCount":9},[],{"intervention":323,"totalTrials":220,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":342},{"trials":329,"activeCount":9},[],{"trials":331,"activeCount":9},[],{"trials":333,"activeCount":9},[],{"trials":335,"activeCount":9},[],{"trials":337,"activeCount":9},[338],{"nctId":314,"briefTitle":315,"status":58,"phases":339,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":340,"interventions":341},[39],[321],[301,323],{"trials":343,"activeCount":9},[],{"intervention":345,"totalTrials":220,"cells":346},"Testosteron",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":355,"NA":365},{"trials":348,"activeCount":9},[],{"trials":350,"activeCount":9},[],{"trials":352,"activeCount":9},[],{"trials":354,"activeCount":9},[],{"trials":356,"activeCount":9},[357],{"nctId":358,"briefTitle":359,"status":58,"phases":360,"primaryCompletion":361,"completion":361,"start":255,"enrollment":362,"conditions":363,"interventions":364},"NCT01160341","Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism",[39],"2010-01",312,[22],[345],{"trials":366,"activeCount":9},[],{"intervention":368,"totalTrials":220,"cells":369},"Sustanon",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":388},{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[],{"trials":375,"activeCount":9},[],{"trials":377,"activeCount":9},[],{"trials":379,"activeCount":9},[380],{"nctId":381,"briefTitle":382,"status":58,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":181,"conditions":386,"interventions":387},"NCT01107067","Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism",[39],"2009-12","2008-06",[22],[368],{"trials":389,"activeCount":9},[],{"intervention":391,"totalTrials":220,"cells":392},"Testosterone enanthate",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":413},{"trials":394,"activeCount":9},[],{"trials":396,"activeCount":9},[],{"trials":398,"activeCount":9},[],{"trials":400,"activeCount":9},[],{"trials":402,"activeCount":9},[403],{"nctId":404,"briefTitle":405,"status":58,"phases":406,"primaryCompletion":407,"completion":407,"start":62,"enrollment":408,"conditions":409,"interventions":410},"NCT01601327","Effects of Medications in Patients With Hypogonadism",[39],"2012-03",119,[20],[391,411,412],"Human chorionic gonadotropin","Testosteron gel",{"trials":414,"activeCount":9},[],{"intervention":411,"totalTrials":220,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":431},{"trials":418,"activeCount":9},[],{"trials":420,"activeCount":9},[],{"trials":422,"activeCount":9},[],{"trials":424,"activeCount":9},[],{"trials":426,"activeCount":9},[427],{"nctId":404,"briefTitle":405,"status":58,"phases":428,"primaryCompletion":407,"completion":407,"start":62,"enrollment":408,"conditions":429,"interventions":430},[39],[20],[391,411,412],{"trials":432,"activeCount":9},[],{"intervention":412,"totalTrials":220,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":449},{"trials":436,"activeCount":9},[],{"trials":438,"activeCount":9},[],{"trials":440,"activeCount":9},[],{"trials":442,"activeCount":9},[],{"trials":444,"activeCount":9},[445],{"nctId":404,"briefTitle":405,"status":58,"phases":446,"primaryCompletion":407,"completion":407,"start":62,"enrollment":408,"conditions":447,"interventions":448},[39],[20],[391,411,412],{"trials":450,"activeCount":9},[],{"intervention":117,"totalTrials":220,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":467},{"trials":454,"activeCount":9},[],{"trials":456,"activeCount":9},[],{"trials":458,"activeCount":9},[],{"trials":460,"activeCount":9},[],{"trials":462,"activeCount":9},[463],{"nctId":110,"briefTitle":111,"status":58,"phases":464,"primaryCompletion":113,"start":104,"enrollment":114,"conditions":465,"interventions":466},[39],[32],[117,87],{"trials":468,"activeCount":9},[],{"intervention":470,"totalTrials":220,"cells":471},"Sustanon 250 mg ampule",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":473,"activeCount":9},[],{"trials":475,"activeCount":9},[],{"trials":477,"activeCount":9},[],{"trials":479,"activeCount":9},[],{"trials":481,"activeCount":9},[],{"trials":483,"activeCount":9},[484],{"nctId":485,"briefTitle":486,"status":58,"phases":487,"primaryCompletion":488,"completion":488,"start":62,"enrollment":489,"conditions":490,"interventions":491},"NCT01758094","Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism",[],"2012-08",25,[20],[470],{"intervention":493,"totalTrials":220,"cells":494},"human chorionic gonadotropin, human menopausal gonadotropin",{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":496,"activeCount":9},[],{"trials":498,"activeCount":9},[],{"trials":500,"activeCount":9},[],{"trials":502,"activeCount":9},[],{"trials":504,"activeCount":9},[],{"trials":506,"activeCount":9},[507],{"nctId":508,"briefTitle":509,"status":58,"phases":510,"primaryCompletion":511,"completion":511,"start":138,"enrollment":512,"conditions":513,"interventions":514},"NCT02728440","Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism",[],"2012-12",30,[20],[493],{"intervention":516,"totalTrials":220,"cells":517},"hCG 1500 IU three times a week",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":519,"activeCount":9},[],{"trials":521,"activeCount":9},[],{"trials":523,"activeCount":9},[],{"trials":525,"activeCount":9},[],{"trials":527,"activeCount":9},[],{"trials":529,"activeCount":9},[530],{"nctId":531,"briefTitle":532,"status":58,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":538},"NCT02042638","The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism",[],"2013-08","2011-01",16,[20],[516,539],"Pregnyl (hCG) ampule 1500 IU\u002Fthree times a week",{"intervention":539,"totalTrials":220,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":543,"activeCount":9},[],{"trials":545,"activeCount":9},[],{"trials":547,"activeCount":9},[],{"trials":549,"activeCount":9},[],{"trials":551,"activeCount":9},[],{"trials":553,"activeCount":9},[554],{"nctId":531,"briefTitle":532,"status":58,"phases":555,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":556,"interventions":557},[],[20],[516,539],{"intervention":559,"totalTrials":220,"cells":560},"Norditropin pen",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":571},{"trials":562,"activeCount":9},[],{"trials":564,"activeCount":9},[],{"trials":566,"activeCount":9},[],{"trials":568,"activeCount":9},[],{"trials":570,"activeCount":9},[],{"trials":572,"activeCount":9},[573],{"nctId":574,"briefTitle":575,"status":58,"phases":576,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT00561769","Luteal Phase Commencing of Growth Hormone",[],"2007-11","2005-01",61,[581],"Infertility",[559]]